An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension

Arzu Ulu, Kin Sing Stephen Lee, Christina Miyabe, Jun Yang, Bruce G. Hammock, Hua Dong, Bruce D. Hammock

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Mediators of antihypertensive actions of docosahexaenoic acid (DHA) are largely unknown. The omega-3 epoxide of DHA, 19, 20-EDP (epoxy docosapentaenoic acid), is metabolized by soluble epoxide hydrolase (sEH), which also metabolizes the anti-inflammatory and antihypertensive arachidonic acid epoxides, epoxyeicosatrienoic acids (EETs). Based in part on plasma levels of EDPs after a DHA-rich diet, we hypothesized that 19, 20-EDP contributes to the antihypertensive actions of DHA in angiotensin-II (Ang-II)-dependent hypertension. Treatment individually with 19, 20-EDP and a potent sEH inhibitor TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) significantly lowered blood pressure (BP) as compared with Ang-II-infused animals. The largest reduction in BP was obtained with the combination of 19, 20-EDP and TPPU, which was more efficacious than the combination of 14, 15-EET and TPPU. Oxylipin profiling revealed that 19, 20-EDP and 14, 15-EET infusion affected not only most metabolites of the P450 pathway but also renal levels of prostaglandin-E2. Our findings suggest that 19, 20-EDP is a mediator of the antihypertensive effects of DHA in Ang-II-dependent hypertension. It seems that 19, 20-EDP requires metabolic stabilization with a sEH inhibitor to be most effective in lowering BP, although both TPPU and 19, 20-EDP are so effective on their own that demonstrating additive or synergistic interactions is difficult.

Original languageEnglish (US)
Pages (from-to)87-99
Number of pages13
JournalJournal of Cardiovascular Pharmacology
Volume64
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Docosahexaenoic Acids
Epoxy Compounds
Angiotensin II
Epoxide Hydrolases
Antihypertensive Agents
Blood Pressure
Hypertension
Oxylipins
Dinoprostone
Arachidonic Acid
Urea
Anti-Inflammatory Agents
Diet
Kidney
Acids
14,15-epoxy-5,8,11-eicosatrienoic acid

Keywords

  • 19,20-epoxy docosapentaenoic acid
  • angiotensin- II'dependent hypertension
  • docosahexaenoic acid
  • omega-3 polyunsaturated fatty acids
  • soluble epoxide hydrolase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. / Ulu, Arzu; Stephen Lee, Kin Sing; Miyabe, Christina; Yang, Jun; Hammock, Bruce G.; Dong, Hua; Hammock, Bruce D.

In: Journal of Cardiovascular Pharmacology, Vol. 64, No. 1, 2014, p. 87-99.

Research output: Contribution to journalArticle

Ulu, Arzu ; Stephen Lee, Kin Sing ; Miyabe, Christina ; Yang, Jun ; Hammock, Bruce G. ; Dong, Hua ; Hammock, Bruce D. / An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. In: Journal of Cardiovascular Pharmacology. 2014 ; Vol. 64, No. 1. pp. 87-99.
@article{dc06b79bcc554e8eb00b6b08e56863bd,
title = "An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension",
abstract = "Mediators of antihypertensive actions of docosahexaenoic acid (DHA) are largely unknown. The omega-3 epoxide of DHA, 19, 20-EDP (epoxy docosapentaenoic acid), is metabolized by soluble epoxide hydrolase (sEH), which also metabolizes the anti-inflammatory and antihypertensive arachidonic acid epoxides, epoxyeicosatrienoic acids (EETs). Based in part on plasma levels of EDPs after a DHA-rich diet, we hypothesized that 19, 20-EDP contributes to the antihypertensive actions of DHA in angiotensin-II (Ang-II)-dependent hypertension. Treatment individually with 19, 20-EDP and a potent sEH inhibitor TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) significantly lowered blood pressure (BP) as compared with Ang-II-infused animals. The largest reduction in BP was obtained with the combination of 19, 20-EDP and TPPU, which was more efficacious than the combination of 14, 15-EET and TPPU. Oxylipin profiling revealed that 19, 20-EDP and 14, 15-EET infusion affected not only most metabolites of the P450 pathway but also renal levels of prostaglandin-E2. Our findings suggest that 19, 20-EDP is a mediator of the antihypertensive effects of DHA in Ang-II-dependent hypertension. It seems that 19, 20-EDP requires metabolic stabilization with a sEH inhibitor to be most effective in lowering BP, although both TPPU and 19, 20-EDP are so effective on their own that demonstrating additive or synergistic interactions is difficult.",
keywords = "19,20-epoxy docosapentaenoic acid, angiotensin- II'dependent hypertension, docosahexaenoic acid, omega-3 polyunsaturated fatty acids, soluble epoxide hydrolase inhibitors",
author = "Arzu Ulu and {Stephen Lee}, {Kin Sing} and Christina Miyabe and Jun Yang and Hammock, {Bruce G.} and Hua Dong and Hammock, {Bruce D.}",
year = "2014",
doi = "10.1097/FJC.0000000000000094",
language = "English (US)",
volume = "64",
pages = "87--99",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension

AU - Ulu, Arzu

AU - Stephen Lee, Kin Sing

AU - Miyabe, Christina

AU - Yang, Jun

AU - Hammock, Bruce G.

AU - Dong, Hua

AU - Hammock, Bruce D.

PY - 2014

Y1 - 2014

N2 - Mediators of antihypertensive actions of docosahexaenoic acid (DHA) are largely unknown. The omega-3 epoxide of DHA, 19, 20-EDP (epoxy docosapentaenoic acid), is metabolized by soluble epoxide hydrolase (sEH), which also metabolizes the anti-inflammatory and antihypertensive arachidonic acid epoxides, epoxyeicosatrienoic acids (EETs). Based in part on plasma levels of EDPs after a DHA-rich diet, we hypothesized that 19, 20-EDP contributes to the antihypertensive actions of DHA in angiotensin-II (Ang-II)-dependent hypertension. Treatment individually with 19, 20-EDP and a potent sEH inhibitor TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) significantly lowered blood pressure (BP) as compared with Ang-II-infused animals. The largest reduction in BP was obtained with the combination of 19, 20-EDP and TPPU, which was more efficacious than the combination of 14, 15-EET and TPPU. Oxylipin profiling revealed that 19, 20-EDP and 14, 15-EET infusion affected not only most metabolites of the P450 pathway but also renal levels of prostaglandin-E2. Our findings suggest that 19, 20-EDP is a mediator of the antihypertensive effects of DHA in Ang-II-dependent hypertension. It seems that 19, 20-EDP requires metabolic stabilization with a sEH inhibitor to be most effective in lowering BP, although both TPPU and 19, 20-EDP are so effective on their own that demonstrating additive or synergistic interactions is difficult.

AB - Mediators of antihypertensive actions of docosahexaenoic acid (DHA) are largely unknown. The omega-3 epoxide of DHA, 19, 20-EDP (epoxy docosapentaenoic acid), is metabolized by soluble epoxide hydrolase (sEH), which also metabolizes the anti-inflammatory and antihypertensive arachidonic acid epoxides, epoxyeicosatrienoic acids (EETs). Based in part on plasma levels of EDPs after a DHA-rich diet, we hypothesized that 19, 20-EDP contributes to the antihypertensive actions of DHA in angiotensin-II (Ang-II)-dependent hypertension. Treatment individually with 19, 20-EDP and a potent sEH inhibitor TPPU (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea) significantly lowered blood pressure (BP) as compared with Ang-II-infused animals. The largest reduction in BP was obtained with the combination of 19, 20-EDP and TPPU, which was more efficacious than the combination of 14, 15-EET and TPPU. Oxylipin profiling revealed that 19, 20-EDP and 14, 15-EET infusion affected not only most metabolites of the P450 pathway but also renal levels of prostaglandin-E2. Our findings suggest that 19, 20-EDP is a mediator of the antihypertensive effects of DHA in Ang-II-dependent hypertension. It seems that 19, 20-EDP requires metabolic stabilization with a sEH inhibitor to be most effective in lowering BP, although both TPPU and 19, 20-EDP are so effective on their own that demonstrating additive or synergistic interactions is difficult.

KW - 19,20-epoxy docosapentaenoic acid

KW - angiotensin- II'dependent hypertension

KW - docosahexaenoic acid

KW - omega-3 polyunsaturated fatty acids

KW - soluble epoxide hydrolase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84904266567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904266567&partnerID=8YFLogxK

U2 - 10.1097/FJC.0000000000000094

DO - 10.1097/FJC.0000000000000094

M3 - Article

C2 - 24691274

AN - SCOPUS:84904266567

VL - 64

SP - 87

EP - 99

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -